# An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males

> **NCT01932528** · PHASE1 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Carcinoid Syndrome

## Interventions

- **DRUG:** 500 mg [14C]-LX1606

## Key facts

- **NCT ID:** NCT01932528
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2013-09
- **Final completion:** —
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2013-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01932528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01932528, "An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01932528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*